In recent weeks, the Sorrento Therapeutics Inc (NASDAQ:SRNE) stock has gained strong momentum. Over the course of the past two weeks, the stock has managed to clock gains of 20%. In light of such steady gains, it might be a good idea for investors to take a closer look at Sorrento.
Back on April 20, the company announced that it successfully completed the enrolment that is meant for the Phase 1b study of the possibility of using infusions of human allogeneic adipose-derived mesenchymal stem cells for treating respiratory failure brought about by COVID 19.
As per the announcement from the company, a total of 10 patients have been enrolled in the study. More importantly, after the study was completed, all the patients were discharged within three days from the hospital. In this regard, it is also necessary to note that after having struggled over the past two months, the Sorrento stock has managed to make a strong comeback now. Investors could consider tracking the stock over the coming days.
Editor in Chief.
Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life